Editorial comment.

摘要

The present article-a preplanned secondary analysis of the REduction by Dutasteride of Prostate Cancer Events (REDUCE) trial-provides unique insights into the natural history of lower urinary tract symptoms (LUTS), the risk of progression, and the effect of the dual 5alpha-reductase inhibitor dutasteride in men with rather low symptoms at baseline and a greater risk of disease progression.